Background

Alzheimer’s disease (AD) is the most common cause of dementia affecting ∼ 5.8 million Americans and 40-50 million people worldwide. Despite the burden of this disease, there is no cure for Alzheimer’s with standard-of-care treatments only able to manage symptoms. Furthermore, clinical diagnosis is imprecise and only suitable for later stages of the disease as it relies on detecting impaired memory and cognitive function, which consequently also results in late intervention. However, changes in neurological biomarkers precede cognitive decline by 15 – 20 years and can thus act as indicators of Alzheimer’s disease enabling early diagnosis and clinical intervention. Though several techniques such as cerebrospinal fluid sampling and various medical imaging methods have demonstrated promise in this regard, none